FindMyKOL
Clinical trialNCT02189499UnknownPhase 2Interventional

Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent

NCT02189499 is a phase 2 interventional trial sponsored by Amaranth Medical Inc.. As of 21 Nov 2026, it has a status the registry marks as unknown. It studies Coronary Artery Disease and Myocardial Ischemia. The registry lists an enrollment of 42 participants at 4 sites in 1 country. The registry lists a start date of 30 Sept 2014 and a primary completion date of 30 Jun 2016.

SponsorAmaranth Medical Inc.Enrollment42Coronary Artery DiseaseMyocardial Ischemia
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT02189499
FieldValue
Registry IDNCT02189499
StatusUnknown
PhasePhase 2
Study typeInterventional trial
Lead sponsorAmaranth Medical Inc.
Enrollment42
Registered sites4
Countries1
ConditionsCoronary Artery Disease and Myocardial Ischemia
Start30 Sept 2014
Primary completion30 Jun 2016
Study completion30 Nov 2020
Last update posted8 Jun 2016

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to evaluate the safety and feasibility of a new coronary artery stent for treating blockages in the arteries supplying blood to the heart muscle. The Amaranth FORTITUDE scaffold releases a drug (sirolimus) to reduce the likelihood of the treated blood vessel developing a new blockage. In addition, the scaffold dissolves away over time, leaving no permanent implant after the blood vessel has healed. This study will will be the first evaluation of this stent in humans.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

  • Juan F Granada, MD

    Skirball Center for Cardiovascular Research, Columbia University Medical Center

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Colombia4 sites
  • Clinica de Marly

    Bogotá

  • Instituto del Corazon

    Bucaramanga

  • Angiografia de Occidente S.A.

    Cali

  • Emmsa Clinica Especializada

    Medellín

Sites by country

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT02189499

Each answer restates registry values shown on this page.

What is NCT02189499?

NCT02189499 is a phase 2 interventional trial sponsored by Amaranth Medical Inc.. It studies Coronary Artery Disease and Myocardial Ischemia.

Who leads NCT02189499?

The registry names Juan F Granada, MD (principal investigator, Skirball Center for Cardiovascular Research, Columbia University Medical Center) as the overall official.

Where does NCT02189499 run?

The registry lists 4 sites in 1 country. Every site with a stated country is in one country: Colombia.

When is NCT02189499 expected to complete?

The registry lists a primary completion date of 30 Jun 2016 and a study completion date of 30 Nov 2020. The sponsor last updated the record on 8 Jun 2016.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.